Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMN35BY)

Drug Name

[3H](-)CGP 12177 Drug Info

Synonyms

UNII-Z7YP8B158Q; CHEMBL36060; Z7YP8B158Q; 4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one; Tocris-1134; Lopac-C-125; AC1O7G0V; GTPL531; SCHEMBL12329633; ZINC3979132; BDBM50098668; NCGC00025024-01; NCGC00015184-01; NCGC00015184-02; CGP-12177, (S)-; (S)-(-)-CGP-12177; UNII-R89UMZ82MJ component UMQUQWCJKFOUGV-VIFPVBQESA-N; 4-(3-tert-Butylamino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one; 95840-76-9; 2H-Benzimidazol-2-one, 4-((2S)-3-((1,1-d

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6603756
CAS Number: CAS 95840-76-9
TTD Drug ID: DMN35BY

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Adrenergic receptor beta-3 (ADRB3)	DTT	ADRB3	2.392	2.655	2.278	1.982

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-3 (ADRB3)	DTT	ADRB3	7.81E-01	0.02	0.16

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 531).
2	Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32.